Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,188 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,266 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04733521 | A Phase 1/2 Study of SC-43 in Combination With Cisplatin | unknown | Phase 1 / Phase 2 | 100 | RaND BiosciencesINDUSTRY | 0 | Feb 2, 2021 | clinicaltrials |
| NCT03146637 | Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer | unknown | Phase 2 | 80 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT03794440 |
| unknown |
| Phase 2 / Phase 3 |
| 595 |
| Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY |
| 1 |
| Jan 22, 2021 |
| clinicaltrials |
| NCT04479527 | Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 34 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 14, 2021 | clinicaltrials |
| NCT04692051 | A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | unknown | Phase 2 | 100 | Huazhong University of Science and TechnologyOTHER | 1 | Dec 31, 2020 | clinicaltrials |
| NCT04183088 | Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 125 | National Taiwan University HospitalOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT04668976 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | unknown | Phase 2 | 100 | Benaroya Research InstituteOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04652492 | Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 72 | Zhongda HospitalOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04627363 | HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 0 | Nov 13, 2020 | clinicaltrials |
| NCT04317248 | "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma | unknown | Phase 2 | 600 | Yuehua HuangOTHER | 1 | Oct 29, 2020 | clinicaltrials |
| NCT03645980 | DKN-01 Inhibition in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 70 | Johannes Gutenberg University MainzOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT04597970 | TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC(OXRI) | unknown | Phase 2 | 66 | Peking University Cancer Hospital & InstituteOTHER | 0 | Oct 22, 2020 | clinicaltrials |
| NCT04454762 | A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function(CaboCHILD) | unknown | Phase 2 | 20 | Johannes Gutenberg University MainzOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT04538313 | A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs | unknown | Phase 1 / Phase 2 | 40 | CAR-T (Shanghai) Cell Biotechnology Co., Ltd.NETWORK | 1 | Sep 4, 2020 | clinicaltrials |
| NCT04527679 | Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT04523402 | Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis | unknown | Phase 2 | 100 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Aug 21, 2020 | clinicaltrials |
| NCT04523662 | Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer | unknown | Phase 2 | 27 | Beijing Tsinghua Chang Gung HospitalOTHER | 0 | Aug 21, 2020 | clinicaltrials |
| NCT04506281 | PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | unknown | Phase 2 | 128 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04297202 | SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma(HCC-009) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT02162914 | Regorafenib Versus Placebo to Treat Cholangiocarcinoma(REACHIN) | unknown | Phase 2 | 66 | Erasme University HospitalOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03943043 | Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 85 | Istituto Clinico HumanitasOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03642561 | Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE | unknown | Phase 2 / Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT04476641 | A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors(DC-CIK) | unknown | Phase 2 | 686 | Sun Yat-sen UniversityOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT04411706 | A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 46 | Xin-Hua XuOTHER | 1 | Jun 24, 2020 | clinicaltrials |
| NCT04333927 | Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer(ACCORD) | unknown | Phase 2 | 92 | Sun Yat-sen UniversityOTHER | 1 | Jun 23, 2020 | clinicaltrials |
| NCT04435977 | Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma(Immunocabo) | unknown | Phase 2 | 46 | Istituto Clinico HumanitasOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04413734 | Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT03592706 | Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy | unknown | Phase 2 / Phase 3 | 60 | Ivy Life Sciences, Co., LtdINDUSTRY | 1 | Apr 16, 2020 | clinicaltrials |
| NCT04080154 | Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma(ALTER-H-002) | unknown | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT04319484 | Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus(LLTHVV) | unknown | Phase 2 / Phase 3 | 108 | RenJi HospitalOTHER | 0 | Mar 24, 2020 | clinicaltrials |
| NCT02533700 | CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL | unknown | Phase 2 | 106 | Shandong Provincial HospitalOTHER_GOV | 1 | Mar 10, 2020 | clinicaltrials |
| NCT04300959 | Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer | unknown | Phase 2 | 80 | Zhejiang Cancer HospitalOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT04273100 | PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC(PLTHCC) | unknown | Phase 2 | 56 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03873532 | A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients | unknown | Phase 2 / Phase 3 | 298 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT04241523 | Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC | unknown | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04227808 | Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma | unknown | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT04193696 | RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC) | unknown | Phase 2 | 39 | Guangxi Medical UniversityOTHER | 0 | Jan 9, 2020 | clinicaltrials |
| NCT03139487 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism(PRIORITY) | unknown | Phase 2 | 176 | Asan Medical CenterOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT04206254 | GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Liver Cancer | unknown | Phase 2 / Phase 3 | 80 | Cure&Sure Biotech Co., LTDINDUSTRY | 0 | Dec 20, 2019 | clinicaltrials |
| NCT04204577 | The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer | unknown | Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Dec 19, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04157140 | Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC | unknown | Phase 2 | 48 | Jinglong ChenOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04168944 | Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 108 | RenJi HospitalOTHER | 0 | Nov 19, 2019 | clinicaltrials |
| NCT04169399 | Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT04162158 | Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 200 | Beijing 302 HospitalOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT04156958 | Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma(FSTAMBTA) | unknown | Phase 2 | 33 | Sichuan UniversityOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT03825705 | A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT04069949 | Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus(STUHCCPVTT) | unknown | Phase 1 / Phase 2 | 39 | Sichuan UniversityOTHER | 0 | Oct 25, 2019 | clinicaltrials |
| NCT04111380 | Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers | unknown | Phase 2 | 30 | Henan Provincial People's HospitalOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT01825824 | Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm | unknown | Phase 2 | 54 | Korea Cancer Center HospitalOTHER | 1 | Sep 20, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Feb 2, 2021source: clinicaltrials